DG DISPATCH - AIDS 2000: Nevirapine Provides Long-term HIV Protection In Babies
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




DG DISPATCH - AIDS 2000: Nevirapine Provides Long-term HIV Protection In Babies

By Ed Susman
Special to DG News

DURBAN, SOUTH AFRICA -- July 14, 2000 -- Nevirapine, when administered to a pregnant mother in labor, has long-term effect in protecting the newborn against transmission of HIV, even if the mother breastfeeds.

At the 13th International AIDS Conference, in Durban, South Africa, doctors reported on a study which compared a short course of nevirapine to AZT in treating HIV-infected pregnant women.

Previous studies showed AZT prevents transmission of the virus from mother to infant during pregnancy, but AZT requires a longer course of treatment and is more costly than nevirapine.

Maxi Owor, MD, a pediatrician at Mulago Hospital in Kampala, gave one nevirapine dose to the mother during labor and one dose to the child after delivery. When compared to the standard AZT treatment, women receiving nevirapine were able to reduce the risk of transmitting the virus to their children by more than 40 percent.

The latest findings stem from the continued follow-up of breastfeeding mothers and their babies enrolled in a clinical trial by the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health.

Last year, results from that trial showed that a short regimen of nevirapine given to both mother and child significantly reduced HIV transmission. The new results show this transmission reduction was sustained even though the infants were breast-fed.

More than 600 women were enrolled in the trial conducted at the teaching hospital of Makerere University in Kampala. The six-week data showed that mothers and infants who received nevirapine had a 42 percent lower risk of HIV transmission when compared with those receiving AZT. At 12 months, the reduction was 39 percent, and preliminary results indicate a reduction of 42 percent after 18 months.

Related Link: nevirapine (Viramune).

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities